# reload+after+2024-01-23 06:45:34.671962
address1§11099 North Torrey Pines Road
address2§Suite 290
city§La Jolla
state§CA
zip§92037
country§United States
phone§858 750 4700
website§https://www.januxrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.
fullTimeEmployees§64
companyOfficers§[{'maxAge': 1, 'name': 'Dr. David Alan Campbell Ph.D.', 'age': 63, 'title': 'President, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 852500, 'exercisedValue': 0, 'unexercisedValue': 14666733}, {'maxAge': 1, 'name': 'Mr. Byron  Robinson J.D., Ph.D.', 'age': 58, 'title': 'Chief Strategy Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 606801, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tighe M. Reardon C.F.A., CPA', 'age': 47, 'title': 'Acting Chief Financial Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tommy  Diraimondo Ph.D.', 'title': 'Executive Director of Research & Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Charles M. Winter', 'age': 54, 'title': 'Chief Technical Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Pennington', 'title': 'General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Brenda  Van Vreeswyk', 'title': 'Head of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andy Hollman Meyer', 'age': 39, 'title': 'Chief Business Officer', 'yearBorn': 1984, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§10
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.983
priceToSalesTrailing12Months§56.21781
currency§USD
dateShortInterest§1702598400
forwardEps§-1.75
pegRatio§0.26
exchange§NGM
quoteType§EQUITY
shortName§Janux Therapeutics, Inc.
longName§Janux Therapeutics, Inc.
firstTradeDateEpochUtc§1623418200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3a638123-d3da-3133-96c7-e6e8cabf84b3
gmtOffSetMilliseconds§-18000000
targetHighPrice§35.0
targetLowPrice§21.0
targetMeanPrice§26.25
targetMedianPrice§24.5
recommendationMean§1.4
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§24.284
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
